Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.

Abemaciclib demonstrated statistically significant OS benefits in one trial (MONARCH-2) and failed to reach significance in another (MONARCH-3), whereas palbociclib did not demonstrate significant OS benefit when combined with endocrine therapy in any phase III trial in HR-positive/HER2-negative MBC (PALOMA-2 and PALOMA-3). 1 , 2 , 3 , 4 Importantly, ribociclib is the only CDK4/6i to demonstrate significant OS benefi

also in 4,113 other papers